Abstract:Despite the rapid advancement in the introduction of new drugs for cancer therapy, the frequent emergence of drug resistance leads to disease progression or tumor recurrence resulting in dismal prognosis. Given that genetic mutations are thought to be important drivers of anti-cancer drug resistance, it is of paramount importance to pin-point mutant genes that mediate drug resistance and elucidate the underlying molecular mechanisms in order to develop novel modalities to surmount chemoresistance and achieve more efficacious and durable cancer therapies. Cumulative evidence suggests that epigenetic alterations, especially those mediated by epigenetic enzymes with high mutation rates in cancer patients, can be a crucial factor in the development of chemoresistance. Mutant epigenetic enzymes have altered enzymatic activity which may directly or indirectly affect the level of histone modifications. This can change chromatin structure and function hence altering the expression of target genes and eventually lead to chemoresistance. In the current review, we summarize epigenetic enzyme mutations and the consequent mechanisms of drug resistance in pre-clinical drug-resistance models and relapsed cancer patient specimens. We also introduce previously unreported mutation sites in the DOT1 domain of DOT1L, which are related to lung cancer drug resistance. It is worth noting that mutations occur not only in domains with enzymatic activity but also in non-catalytic regions. Each protein domain is an evolutionarily conserved region with independent functional properties. This may provide a rationale for the potential development of small molecule inhibitors which target various functional domains of epigenetic enzymes. Finally, based on the multitude of mechanisms of drug resistance, we propose several therapeutic strategies to reverse or overcome drug-resistance phenotypes, with the aim to provide cancer patients with novel efficacious combination therapeutic regimens and strategies to improve patient prognosis.

Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance

Protein Arginine Methyltransferases (PRMTs): Orchestrators of Cancer Pathogenesis, Immunotherapy Dynamics, and Drug Resistance

Mechanism and Potential Therapeutic Strategies Based on PRMT5 in Chemotherapy-Induced Drug Resistance in Non-Small Cell Lung Cancer

Protein arginine methylation: from enigmatic functions to therapeutic targeting

Protein arginine methyltransferases: promising targets for cancer therapy

Medicinal chemistry strategies targeting PRMT5 for cancer therapy.

The Role of PRMT1 in Cellular Regulation and Disease: Insights into Biochemical Functions and Emerging Inhibitors for Cancer Therapy

PRMT1 in human neoplasm: cancer biology and potential therapeutic target

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

Overview of PRMT1 modulators: Inhibitors and degraders

Peptide-based Strategies for Overcoming Multidrug-Resistance in Cancer Therapy

Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy

Small Molecule Inhibitors of Protein Arginine Methyltransferases

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer

Protein Arginine Methyltransferase 5: a Potential Cancer Therapeutic Target

The role of protein arginine methylation 5 in DNA damage repair and cancer therapy

Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer

An updated patent review of protein arginine N-methyltransferase inhibitors (2019-2022)

Methylation modification of non-histone proteins in breast cancer: an emerging targeted therapeutic strategy

A patent review of PRMT5 inhibitors to treat cancer (2018 - present)